Nanobiotix approval for liver cancer trials

The French nano-medical technology company, Nanobiotix has been given the green light for a phase I/II clinical trial in patients with advanced forms of liver cancer. The multinational, non-randomized, study will evaluate the use of NBTXR3 with high precision radiation therapy. This type of treatment is the safest and most modern radiotherapy currently available for the treatment of malignant liver tumors. The CEO, Laurent Levy, tells Proactiveinvestors that their unique suite of Nano-medical products is being used in a wider range of malignant cancers.